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Introduction
============

The identification of potential clinical indicators that predict patient outcomes is very important in current medical practice \[[@REF1],[@REF2]\]. There are multiple laboratory tests, clinical scores, and clinical indices that have different ranges of accuracy, and they may not be applicable in all clinical scenarios \[[@REF1],[@REF2],[@REF3]\]. It has been established that elevated lactate levels and glucose levels, independently, are directly related to increased patient morbidity, length of stay (LOS), mortality, etc. \[[@REF4]\]. These two basic laboratory tests are readily available in most institutions in developed countries. Their combined use has not been extensively studied, and we hypothesized that their combined use may enhance our ability to identify sicker patients who would require more intensive management to improve their outcomes. 

Materials and methods
=====================

This is a single-center, retrospective study. It included all adults (≥18 years old) admitted to University Medical Center in Lubbock, Texas, from October 1, 2015 to September 30, 2016, whose admission glucose and lactate levels were recorded. Requests for laboratory tests were based on individual patient management decisions. Patients who were \<18 years of age and \>89 years of age were excluded. General demographic information was collected. This included age, gender, LOS, and mortality. University Medical Center is a 500-bed referral center in West Texas. 

The patients were stratified according to their lactate levels into three categories: lactate levels of \<2 mmol/L; lactate levels of 2.0-4.0 mmol/L; and lactate levels \>4.0 mmol/L. The respective LOS and mortality were calculated for each category. The patients were then classified according to their respective quartiles for their glucose and lactate levels, and their respective LOS and mortality were calculated. Patients were also classified according to their glucose/lactate molar ratios into quartiles, with their LOS and mortality for each quartile subsequently calculated.

Finally, the patients were arbitrarily classified according to their paired glucose and lactate levels. We determined the following categories: normal lactate: \<2 mmol/L; high lactate: 2.0-4.0 mmol/L; and very high lactate: \>4 mmol/L. These were paired with glucose levels classified as follows: normal glucose: 60-140 mg/dL; high glucose: 140-200 mg/dL; and very high glucose: \>200 mg/dL. The respective LOS and mortality were calculated for each group.

Descriptive statistics were used to describe the characteristics of the study cohort. Categorical variables were summarized as frequencies, and continuous variables were summarized using medians and quartiles or percentiles, as appropriate. Univariate logistic regression was used to test if there is a significant association between mortality and assigned categories. Odds ratios (ORs) were calculated to evaluate these associations. Comparisons of LOS across categories were performed using the Kruskal-Wallis rank sum test. The statistically significant level was set at 0.05. Multiple testing adjustment was not performed. Analyses were performed using SAS software, Windows version 9.3 (SAS Institute, Cary, NC). 

Results
=======

A total of 5,436 patients were included in this study. The median age was 58 years (25th-75th percentile: 44-69 years); 57% of the patients were male. The median LOS was 6 days (25th-75th percentile: 3-11 days). The overall in-hospital mortality was 11.04%. The distribution of glucose, lactate, and glucose/lactate ratios for representative diagnoses are shown in Table [1](#TAB1){ref-type="table"}.

###### Distribution of glucose, lactate levels, and glucose/lactate molar ratios of most representative diagnoses

\*Numbers in parentheses represent the 25th and 75th percentiles

  -------------------------------------------------------------- -------------------- ------------------- ---------------------------
  Category                                                       Glucose median\*     Lactate median\*    Glucose/lactate median\* 
  Sepsis (n = 799)                                               132 (105.0, 202.5)   1.8 (1.2, 2.8)      4.54 (2.75, 7.01)
  Pneumonia (n = 118)                                            125 (103.0, 163.5)   1.3 (0.9, 1.6)      5.60 (4.05, 7.96)
  Chronic obstructive pulmonary disease exacerbation (n = 159)   123 (108.0, 149.5)   1.3 (1.0, 2.1)      5.26 (3.48, 7.59)
  Acute kidney failure (n = 81)                                  116 (92.0, 165.0)    1.4 (1.1, 1.9)      5.01 (3.62, 8.15)
  Urinary tract infection (n = 28)                               138 (106.8, 246.5)   1.1 (0.9, 1.7)      6.74 (5.13, 10.19)
  Gastrointestinal bleed (n = 55)                                121 (98.5, 162.5)    1.7 (1.2, 2.6)      4.69 (2.19, 8.01)
  Coronary artery disease (n = 191)                              118 (95.0, 149.0)    1.3 (1.0, 1.7)      5.17 (3.62, 7.32)
  Acute heart failure (n = 102)                                  127 (108.3, 189.5)   1.4 (1.1, 1.9)      5.39 (3.85, 7.85)
  Pancreatitis (n = 30)                                          144 (116.5, 236.5)   1.4 (0.9, 2.1)      6.81 (4.23, 9.03)
  Acute respiratory failure (n = 211)                            130 (104.0, 191.5)   1.5 (1.1, 2.3)      5.11 (3.38, 7.21)
  -------------------------------------------------------------- -------------------- ------------------- ---------------------------

The patients were stratified according to their lactate levels. Those with a lactate level of \<2.0 mmol/L had a mortality rate of 7.18%; those with a lactate level between 2.0-4.0 mmol/L had a mortality of 13.16%; and those with a lactate level of \>4 mmol/L had a mortality of 36.04%. Specifically, when treated as a continuous predictor, a one-unit increase in lactate was associated with a 32% increase in the odds of mortality (p: \<0.001) (Table [2](#TAB2){ref-type="table"}).

###### Outcomes based on lactate level

¶The distributions of patient age, LOS, and mortality differ among the lactate percentile groups

\*Numbers in parentheses are the 25th and 75th percentiles; \*\*numbers in parentheses are percentage figures

  --------------------- ---------------------- ------------------------- ---------------------- ------------- ----------
  Lactate (mmol/L)      Lactate level: \<2.0   Lactate level: 2.0--4.0   Lactate level: \>4.0   All           P-value¶
  Number                3,763                  1,193                     480                    5,436          
  Male/female           2,105/1,658            707/486                   284/196                3,096/2,340   0.077
  Median age, years\*   60 (47, 70)            55 (39, 67)               56 (42, 67)            58 (44, 69)   \<0.001
  Median LOS, days\*    6 (4, 11)              6 (3, 11)                 5 (2, 10)              6 (3, 11)     \<0.001
  Mortality\*\*         270 (7.18)             157 (13.16)               173 (36.04)            600 (11.04)   \<0.001
  --------------------- ---------------------- ------------------------- ---------------------- ------------- ----------

The patients were next divided into quartiles according to the glucose levels. The mortality rate was as follows: 1st quartile (glucose: \<102 mg/dl): 9.44%; 2nd quartile (glucose: 102-125 mg/dl): 9.26%; 3rd quartile (glucose: 125-173 mg/dL); 10.53%; and 4th quartile (glucose: ≥173 mg/dl): 14.87%. Specifically, when comparing the patients in quartiles 1, 2 and 3, the patients in the 4th quartile had a 68%, 71%, and 49% increase in the odds of mortality, respectively (p: \<0.001). The LOS was shorter for those in the 4th quartile (p: \<0.001) (Table [3](#TAB3){ref-type="table"}).

The patients were also divided into quartiles according to the lactate levels. The mortality rate was as follows: 1st quartile (lactate: \<1.05 mmol/L): 5.56%; 2nd quartile (lactate: 1.05-1.45 mmol/L): 6.83%; 3rd quartile (lactate: 1.45-2.23 mmol/L): 9.72%; and 4th quartile (lactate: \>2.23 mmol/L): 21.95%. Compared with patients in quartiles 1, 2 and 3, the patients in the 4th quartile had a 377%, 284%, and 161% increase in the odds of mortality, respectively (p: \<0.001). The LOS was shorter for those in the 4th quartile (p: \<0.001) (Table [3](#TAB3){ref-type="table"}).

When the patients were divided into quartiles by their glucose/lactate molar ratios, the mortality was as follows: 1st quartile (\<3.3): 19.72%; 2nd quartile (3.3-5.1): 9.35%; 3rd quartile (5.1-7.5): 8.98%; and 4th quartile (\>7.5): 6.11%. When comparing the patients in the 1st quartile glucose/lactate molar ratio, the patients in quartiles 2, 3, and 4 had a 58%, 60%, and 74% decrease in the odds of mortality (p: \<0.001) (Table [3](#TAB3){ref-type="table"}).

###### Outcomes based on glucose and lactate levels in quartiles

Q: quartiles; LOS: length of stay

\*Numbers in parentheses are the 25th and 75th percentiles; \*\*numbers in parentheses are percentage figures

  --------------------------------- ------------- ---------------- ---------------- ------------- ---------
  Patient details                                                                                 
  Glucose, mg/dl                    Q1 (\<102)    Q2 (102-125)     Q3 (125-173)     Q4 (\>173)    P-value
  Number                            1,324         1,360            1,387            1,365          
  Male/female                       704/620       785/575          866/521          741/624       \<0.001
  Median age, years\*               58 (43, 68)   59 (45, 71)      60 (46, 71)      57 (44, 67)   \<0.001
  Median LOS, days\*                6 (3, 11)     6 (3, 11)        6 (4, 11)        5 (3, 10)     \<0.001
  Mortality\*\*                     125 (9.44)    126 (9.26)       146 (10.53)      203 (14.87)   \<0.001
  Lactate, mmol/L                                                                                 
  Lactate                           Q1 (\<1.05)   Q2 (1.05-1.45)   Q3 (1.45-2.23)   Q4 (\>2.23)   P-value
  Number                            1,330         1,376            1,368            1,362          
  Male/female                       691/639       784/592          809/559          812/550       \<0.001
  Median age, years\*               60 (47, 70)   60 (46, 70)      59 (45, 70)      55 (40, 66)   \<0.001
  Median LOS, days\*                6 (4, 10)     6 (4, 11)        6 (3, 11)        5 (3, 11)     \<0.001
  Mortality\*\*                     74 (5.56)     94 (6.83)        133 (9.72)       299 (21.95)   \<0.001
  Glucose/lactate in molar ratios                                                                 
  Glucose/lactate molar ratio\*     Q1 (\<3.3)    Q2 (3.3-5.1)     Q3 (5.1-7.5)     Q4 (\>7.5)    P-value
  Number                            1,359         1,359            1,359            1,359          
  Male/female                       815/544       804/555          748/611          729/630       0.001
  Median age, years\*               57 (40, 67)   59 (43.5, 70)    60 (48, 71)      58 (46, 68)   \<0.001
  Median LOS, days\*                6 (3, 12)     6 (3, 10)        6 (4, 11)        6 (3, 10)     0.621
  Mortality\*\*                     268 (19.72)   127 (9.35)       122 (8.98)       83 (6.11)     \<0.001
  --------------------------------- ------------- ---------------- ---------------- ------------- ---------

When the patients were classified according to glucose and lactate levels, the lowest mortality was in the group with normal glucose/lactate levels (6.39%); the highest mortality was in the groups with normal glucose/very high lactate (32.43%), high glucose/very high lactate (34.04%), and very high glucose/very high lactate levels (39.15%). In the normal glucose category, compared with patients in normal and high lactate groups, patients in the very high lactate group had a 603% and 212% increase in the odds of mortality (p: \<0.001), respectively. In the high glucose category, compared with patients in the normal and high lactate groups, patients in the very high lactate group had a 345% and 295% increase in the odds of mortality (p: 0.001), respectively. In the very high glucose category, compared with patients in normal and high lactate groups, patients in the very high lactate group had a 897% and 290% increase in the odds of mortality (p: \<0.001), respectively. In addition, patients in the very high glucose/very high lactate group had the shortest LOS (median: 4; 25th-75th percentiles: 2-8) (Table [4](#TAB4){ref-type="table"}).

###### Inpatient mortality comparison between glucose and lactate levels

NG: normal glucose (60-140 mg/dl); HG: high glucose (140-200 mg/dl); VHG: very high glucose (\>200 mg/dl) 

NL: normal lactate (\<2 mmol/L); HL: high lactate (2.0-4.0 mm/L); VHL: very high lactate (\>4.0 mmol/L)

LOS: length of stay; \*numbers in parentheses are the 25th and 75th percentiles; \*\*numbers in parentheses are percentage figures

  ---------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------
  Glucose/lactate categories                                                                                                                   
  Glucose/lactate groups       NG, NL        NG, HL        NG, VHL       HG, NL        HG, HL        HG, VHL       VHG, NL       VHG, HL       VHG, VHL
  Number                       2,457         593           185           722           277           94            561           318           189
  Male/female                  1,379/1078    361/232       103/82        420/302       176/101       62/32         292/269       167/151       115/74
  Age, years\*                 59 (46, 70)   55 (37, 67)   57 (46, 69)   63 (51, 72)   55 (38, 66)   58 (43, 70)   57 (44, 66)   53 (43, 66)   54 (40, 64)
  LOS, days\*                  6 (4, 11)     6 (3, 11)     5 (3, 12)     6 (4, 11)     6 (3, 11)     6 (2, 14)     6 (3, 11)     5 (3, 10)     4 (2, 8)
  Mortality\*\*                157 (6.4)     79 (13.3)     60 (32.4)     75 (10.4)     32 (11.5)     32 (34)       34 (6.1)      45 (14.1)     74 (39.1)
  ---------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------

The area under the receiver operating characteristic curves (AUROCs) comparing glucose levels, lactate levels, and glucose/lactate ratios shows a higher AUROCs for lactate levels and glucose/lactate levels when compared to glucose levels alone, indicating better performance of lactate levels and glucose/lactate ratios for predictors for mortality (Figure [1](#FIG1){ref-type="fig"}).

![Area under the receiver operating characteristic curves (AUROCs) comparing glucose, lactate, and glucose/lactate ratio\
Panel A, B, and C show the AUROCs comparing the performance of glucose levels (panel A), lactate levels (panel B), and glucose/lactate ratios (panel C), showing a better performance of lactate and glucose/lactate ratios when compared with glucose alone as predictor of mortality](cureus-0011-00000006027-i01){#FIG1}

Discussion
==========

In this study, we found that the combination of two well-known markers provides valuable information in the early identification of patients with worse outcomes. The group of patients with a combination of very high glucose and very high lactate had the highest mortality in the study cohort. Our results indicate that this combination provides better identification of the sickest patients when compared to either lactate or glucose levels alone.

It has been well established that elevated lactate levels are associated with increased morbidity, LOS, and mortality \[[@REF4],[@REF5],[@REF6]\]. Hyperlactatemia usually occurs when lactate production exceeds lactate clearance. The most common cause is tissue hypoxia, in which lactate is the end product of glycolysis under anaerobic conditions. But this can also occur in disorders unrelated to tissue hypoxia (type B lactic acidosis) \[[@REF7],[@REF8],[@REF9]\]. There is a direct relationship between lactate levels and poor outcomes \[[@REF4]\]. Some studies have reported mortality between 75-100% when lactate levels exceed \>10 mmol/L \[[@REF7],[@REF8]\]. This association has been studied in several clinical scenarios, especially in septic patients, but may also be applicable in patients in other clinical settings, such as emergency room patients, patients with acute coronary syndrome, cardiogenic shock, gastrointestinal bleeding, advanced age, trauma, and postsurgical patients, etc. \[[@REF3],[@REF4],[@REF10],[@REF11],[@REF12],[@REF13]\]. Shetty et al. found that the combination of lactate plus quick Sepsis Related Organ Failure Assessment (qSOFA) improved sensitivity in identifying adverse outcomes in suspected septic patients \[[@REF1]\]. The optimal lactate cut-off value and the timing of lactate measurement to stratify the sickest patients are still unclear. Larger reductions from baseline lactate levels are associated with better outcomes \[[@REF3],[@REF7],[@REF9],[@REF11]\].

The relationship between increased glucose levels and patient outcomes has also been studied, and there is evidence supporting the association of high glucose values with increased morbidity, a longer length of hospitalization, increased readmission, and worse outcomes \[[@REF14],[@REF15],[@REF16],[@REF17]\]. Some studies suggest that these relationships exist independently of a known diagnosis of diabetes \[[@REF15],[@REF18]-[@REF20]\]. The association of hyperglycemia and worse outcomes seems to be stronger when it occurs in non-diabetic patients \[[@REF16],[@REF20]\]. Glynn et al. found that among the patients evaluated in the emergency room, abnormal glucose values were associated with increased mortality in non-diabetic patients but not in diabetic patients \[[@REF2]\]. Abnormally low glucose levels, especially in the ICU, have also been associated with increased mortality \[[@REF2]\]. It is unclear if one or multiple glucose values enhance the ability to triage patients, but Haddadin et al. found that even a single admission of blood glucose could predict increased mortality at 1 year in a mixed cohort of diabetic and non-diabetic patients \[[@REF19]\].

These associations may be related to the metabolic changes caused by an acute illness in glucose and lactate metabolism \[[@REF17],[@REF21],[@REF22]\]. It has also been reported that multiple alterations in the glycolysis and gluconeogenesis pathways may contribute to elevated glucose levels \[[@REF21]-[@REF23]\]. Hyperglycemia per se has been associated with immunologic, metabolic, and microvascular changes \[[@REF18],[@REF22]\]. All of these factors may contribute to a simultaneous elevation of both markers in some critically ill patients. 

Very few studies have analyzed combined glucose and lactate levels as predictors of patient outcomes. Kaukonen et al. found that there is an independent association with hyperglycemia and hyperlactatemia and increased mortality. But the association of hyperglycemia disappeared when hyperlactatemia was considered in combination, suggesting that elevated lactate levels may have a stronger association with poor outcomes \[[@REF21]\]. Green et al. in their assessment of the association of hyperglycemia and hyperlactatemia found that mortality risk did not increase unless hyperglycemia was associated with hyperlactatemia \[[@REF23]\]. Van Vught et al. reported that the association of hyperglycemia and mortality was lost after adjustment for lactate only in non-diabetic patients \[[@REF18],[@REF22]\]. In our study, we did identify sicker patients when both laboratory test results were used in combination. This may be explained by the different patient populations used in these studies. The previous studies utilized these markers in emergency rooms and ICUs, respectively; we used them in all patients admitted to our hospital.

We found a decreased LOS in the groups with the highest glucose, lactate, or both. The explanation for these results is uncertain. This is in contrast to previously published studies, where elevated lactate levels have been associated with increased LOS \[[@REF4]\]. One explanation might be the severity of illness and imminent demise; another explanation might be that these groups included a significant number of patients with diabetic ketoacidosis or hyperosmolar hyperglycemic state who usually have a decreased LOS. The findings between glucose/lactate molar ratios show a novel representation of data that clearly shows that the patients in the first quartile (i.e., those with the highest lactate in proportion to glucose) have increased mortality. Interestingly, the LOS was not affected by this representation of the data.

Some of the strengths of this study include a large population sample, with patients included from multiple clinical settings and services. The authors recognize the limitations of a retrospective study, including the inability to discriminate stress-induced hyperglycemia from diabetes mellitus (lack of a glycosylated hemoglobin value), the lack of serial measurements of lactate and glucose values, and the inability to determine the causes of death.

Conclusions
===========

The combined use of glucose and lactate levels provides useful information for early-risk stratification to identify those patients with worse clinical outcomes. Patients with very high glucose and very high lactate levels need more evaluation and intensive care.
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